In a groundbreaking development, Adial Pharmaceuticals, Inc. (NASDAQ: NASDAQ:ADIL ) has unveiled promising findings in the treatment of Alcohol Use Disorder (AUD) with its lead investigational drug, AD04 (low-dose ondansetron). A recently published peer-reviewed article showcases the remarkable clinical results, robust safety profile, and exceptional patient...